Our Work/Private Sector/Life Sciences

Life Sciences

Bridge Partners is a leading national executive search firm with an unrivaled track record of guiding and implementing an inclusive search process, centering both our work and our own culture in equity. For over two decades our clients have trusted us with their senior leadership assignments because of our consistent delivery of superior results.

We partner with life sciences, biotechnology, and pharmaceutical companies to recruit senior leaders who bring strategic vision, operational rigor, and a deep commitment to inclusion. Please reach out through the form to schedule a time to speak with our team about your search needs.

Shinder Dhillon, Head of Diversity, Equity & Inclusion, Seagen
Featured Placement
Shinder Dhillon
Head of Diversity, Equity & Inclusion, Seagen
Our clients include
Howard Hughes Medical Institute (HHMI)
American Society of Clinical Oncology (ASCO)
Kaiser Permanente
UPMC
  • Howard Hughes Medical Institute (HHMI)
  • American Society of Clinical Oncology (ASCO)
  • Kaiser Permanente
  • UPMC
Featured Placement

Head of Diversity, Equity & Inclusion, Seagen

Shinder Dhillon
Our Placement

Shinder Dhillon

Head of Diversity, Equity & Inclusion · Seagen

Bridge Partners is pleased to announce the appointment of Shinder Dhillon as Head of Diversity, Equity & Inclusion at Seagen.

Ms. Dhillon most recently served as Vice President, Inclusion, Diversity & Equity of Vontier Corporation. She previously spent time at Fortive Corporation and several years at Microsoft. As Head of Diversity, Equity, and Inclusion of Seagen, Shinder will define, lead, and execute the company’s DEI strategy, ensuring Seagen offers a powerful, inclusive experience for all its employees and delivers the diverse talent and capabilities needed to achieve their business strategy. 

Ms. Dhillon holds a Bachelor of Science from Brunel University and is a member of the Chartered Institute of Personnel & Development in the UK. 

About Seagen

Seagen (NASDAQ: SGEN) is a global biotechnology company that develops and commercializes transformative cancer therapies. Driven by a singular mission—to make a difference for people impacted by cancer, Seagen is an industry leader in antibody–drug conjugate (ADC) technology. Seagen pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of their four approved medicines are built on this technology. 

Read the full placement announcement ↗
Connect with our team

Let’s talk about your next leader.

Please reach out through the form to schedule a time to speak with our team about your search needs.

Certified B Corporation WBENC Certified Women's Business Enterprise
Please enable JavaScript in your browser to complete this form.

What is 7+5?